Revolution Medicines is a clinical-stage precision oncology company headquartered in Redwood City, California, developing targeted therapies for RAS-addicted cancers. Its pipeline centers on RAS(ON) inhibitors — including daraxonrasib (RMC-6236), zoldonrasib (RMC-9805), and elironrasib (RMC-6291) — designed to directly target the active, GTP-bound… - View it on GitHub